Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines

Scandinavian Journal of Urology and Nephrology

Volumn 43, Issue 2, 2009, Pages 98-103

  Ullén, Anders ^a,c   Schwarz, Stephan ^a   Lennartsson, Lena ^a   Kälkner, Karl Mikael ^a   Sandström, Per ^a   Costa, Fernanda ^a   Lennernäs, Bo ^b   Linder, Stig ^a   Nilsson, Sten ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apoptosis; Bisphosphonates; Kidney cancer; Skeletal metastases; Zoledronic acid

Indexed keywords

ANTIGEN; CASPASE; CASPASE INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M30; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUOROMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; INCUBATION TIME; KIDNEY CANCER; METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN INDUCTION; QUANTITATIVE ANALYSIS;

APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; CARCINOMA, RENAL CELL; CASPASES; CELL LINE, TUMOR; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUOROMETRY; HUMANS; IMIDAZOLES; KIDNEY NEOPLASMS;

EID: 61349126550     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/00365590802475904     Document Type: Article

References (34)

1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75.
2. Zekri J, Ahmed N, Coleman RE, Hancock BW. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 2001;19:379-82.
3. Rini BI, Vogelzang NJ, Dumas MC, Wade JL III, Taber DA, Stadler WM. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 2000;18:2419-26.
4. Liu JH, Yang MH, Fan FS, Yen CC, Wang WS, Chang YH, et al. Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study. Urology 2001;57:650-4.
5. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408-17.
6. Rini BI. New approaches in advanced renal cell carcinoma. Urol Oncol 2005;23:65-6.
7. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
8. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-24.
9. Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res 2004; 10:6397-403s.
10. Michaelson MD, Rosenthal DI, Smith MR. Long-term bisphosphonate treatment of bone metastases from renal cell carcinoma. J Clin Oncol 2004;22:4233-4.
11. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357-63.
12. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998; 12:220-9.
13. Shipman CM, Rogers MJ, Apperley JF, Graham R, Russell G, Croucher PI. Anti-tumour activity of bisphosphonates in human myeloma cells. Leuk Lymphoma 1998;32:129-38.
14. Shipman CM, Rogers MJ, Vanderkerken K, Van Camp B, Graham R, Russel G, et al. Bisphosphonates - mechanisms of action in multiple myeloma. Acta Oncol 2000;39:829-35.
15. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;15: 2211-21.
16. Dumon JC, Journé F, Kheddoumi N, Lagneaux L, Body JJ. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol 2004;45:521-8; discussion 528-9.
17. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001;61:2602-8.
18. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003;9:295-306.
19. Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998;58: 5294-7.
20. Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 2003;170: 246-52.
21. Green J. Bisphosphonates: preclinical review. Oncologist 2004;9(Suppl 4):3-13.
22. Mönkkönen H, Lehenkari PP, Kellinsalmi M, Hassinen IE, Auriola S, Vepsäläinen J, et al. A new mechanism of action for bisphosphonates: Apppi dedicated cytotoxicity of N-BPs. Bone 2004;34:S66-7.
23. Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992;50:177-85.
24. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001;84:1126-34.
25. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459-68.
26. Ullén A, Lennartsson L, Harmenberg U, Hjelm-Eriksson M, Kälkner KM, Lennernäs B, et al. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 2005;44:644-50.
27. Witters LM, Crispino J, Fraterrigo T, Green J, Lipton A. Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol 2003;26:S92-7.
28. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-105.
29. Lin PY, Fosmire SP, Park SH, Park JY, Baksh S, Modianom JF, et al. Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. Mol Cancer 2007;6:16.
30. Nygren P, Larsson R. Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators. Int J Cancer 1991;48:598-604.
31. Reu FJ, Leaman DW,Maitra RR, Bae SI, Cherkassky L, Fox MW, et al. Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. Cancer Res 2006;66:2785-93.
32. Bivén K, Erdal H, Hägg M, Ueno T, Zhou R, Lynch M, et al. A novel assay for discovery and characterization of proapoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 2003;8:263-8.
33. Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 2007;56:399-404.
34. Pandha H, Birchall L, Meyer B, Wilson N, Relph K, Anderson C, et al. Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines. J Urol 2006;176: 2255-61.